Neurotherapeutic Applications of Antiviral Compounds

The present inventive concept leverages the core technology of the original patent to develop novel therapeutic approaches for treating neurological disorders, neuroinflammation, neurodegenerative diseases, and anxiety disorders, thereby expanding the scope of the original invention.

The original patent disclosed compounds and compositions useful for treating coronavirus-associated diseases. However, the patent did not explore the potential of these compounds in addressing neurological disorders. The present inventive concept addresses this limitation by applying the core technology to develop novel therapeutic approaches for neurological disorders, thereby providing a new avenue for treatment.

The inventive concept involves the use of compounds represented by Formula I, which exhibit antiviral and/or anti-inflammatory effects on neurological cells. These compounds can be administered via various routes, including nasal sprays, to prevent neuroinflammation and treat neurodegenerative diseases. The compounds can also be formulated with neuroprotective agents to enhance their therapeutic efficacy. Furthermore, the inventive concept encompasses the use of nanoparticle formulations and transcranial magnetic stimulation devices to deliver the compounds to the brain, thereby enhancing their bioavailability and therapeutic effect.

The present inventive concept is novel and non-obvious over the original patent because it applies the core technology to an entirely new field of neurological disorders, which was not contemplated in the original patent. The inventive concept involves the identification of new therapeutic applications, new routes of administration, and new formulations, which are not obvious from the original patent.

Alternative embodiments of the inventive concept may involve the use of different compounds, different routes of administration, or different formulations. For example, the compounds may be administered orally or intravenously, or they may be formulated with other neuroprotective agents or anti-inflammatory compounds. Additionally, the inventive concept may be adapted for use in treating other neurological disorders, such as Parkinson's disease or Alzheimer's disease.

The present inventive concept has significant commercial potential in the field of neurological disorders, which is a large and growing market. The inventive concept may be developed into novel therapeutic products, such as nasal sprays or nanoparticle formulations, which could be marketed to pharmaceutical companies or healthcare providers. The market potential is substantial, given the high incidence and prevalence of neurological disorders, and the lack of effective treatments for these disorders.